Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Alnylam Pharmaceuticals, Inc. et al V. Tekmira Pharmaceuticals Corporation
Case Number:
1:12-cv-10087
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
November 13, 2012
Alnylam Puts Up $65M To End Tekmira Trade Secrets Battle
Alnylam Pharmaceuticals Inc. has agreed to pay $65 million to Tekmira Pharmaceuticals Corp. as part of a licensing agreement settling a lawsuit that accused it of misappropriating Tekmira's trade secrets related to gene-silencing therapeutics, the companies announced Monday.
-
September 25, 2012
McDermott Gets Go-Ahead To Work Tekmira Patent Case
A Massachusetts federal judge ruled Monday that a McDermott Will & Emery LLP attorney's past work for Tekmira Pharmaceuticals Corp. was not substantially related to a patent suit brought against Tekmira by a company represented by the firm, allowing McDermott to remain in the case.
-
May 30, 2012
Tekmira Seeks DQ Of McDermott For Past Patent Work
Tekmira Pharmaceuticals Corp. on Tuesday sought the disqualification of Alnylam Pharmaceuticals Inc. counsel McDermott Will & Emery LLP, saying that a McDermott attorney's past work for Tekmira represents a conflict of interest with Alnylam's molecule patent infringement case against the genetics company.
-
January 18, 2012
Alnylam Claims Tekmira Infringed RNAi Tech Patents
Alnylam Pharmaceuticals Inc. filed suit Tuesday in Massachusetts federal court against Tekmira Pharmaceuticals Corp., alleging Canada-based Tekmira infringed six patents by selling gene-therapy-related molecules to pharmaceutical giant Bristol-Myers Squibb Co.